Head to Head Analysis: Nephros (NEPHD) and Its Rivals

Nephros (OTCMKTS: NEPHD) is one of 127 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Nephros to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, dividends, profitability, risk and valuation.

Insider & Institutional Ownership

51.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 6.8% of Nephros shares are owned by insiders. Comparatively, 15.2% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Nephros and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nephros 0 0 0 0 N/A
Nephros Competitors 933 3160 5358 281 2.51

As a group, “Surgical & medical instruments” companies have a potential upside of 19.91%. Given Nephros’ peers higher possible upside, analysts plainly believe Nephros has less favorable growth aspects than its peers.

Profitability

This table compares Nephros and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nephros -52.25% -56.46% -36.62%
Nephros Competitors -674.05% -108.98% -22.27%

Risk & Volatility

Nephros has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Nephros’ peers have a beta of 1.00, suggesting that their average share price is 0% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nephros and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nephros $5.69 million -$3.40 million -11.57
Nephros Competitors $1.43 billion $145.31 million -13.22

Nephros’ peers have higher revenue and earnings than Nephros. Nephros is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Nephros peers beat Nephros on 7 of the 10 factors compared.

Nephros Company Profile

Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; hemodiafilters for use as dialyzers in hemodialysis treatment; and water filters to food service, hospitality, and convenience store markets under the AETHER brand name. The company was founded in 1997 and is headquartered in South Orange, New Jersey.

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.